SSRIs

SSRIs
Formula	N/A
Class
Administration	Oral
Solubility
Legal status	Rx
Brand names	Zoloft, Lexapro, Prozac, Celexa, Paxil, Luvox
Bioavailability
Recommended dose	N/A
Upper limit	N/A
LD50
Ray's verdict	Generally hurts Not safe to supplement

Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs commonly prescribed as antidepressants and anxiolytics. While mainstream psychiatry often views depression as the result of a "chemical imbalance" (specifically a lack of serotonin, frequently mischaracterized as the "happy hormone"), the bioenergetic perspective offers a diametrically opposed view.

According to Ray Peat, serotonin is a hormone of stress, hibernation, and metabolic suppression. In this framework, SSRIs, by increasing serotonin concentration in the synaptic cleft, do not correct a deficiency. Instead, they can exacerbate metabolic stress, reduce cellular energy production (mitochondrial respiration), and act synergistically with estrogen and prolactin.

Uncontrolled serotonin is a major factor in destructive, seemingly uncontrolled aggression…. inclinations of the same sort when combined with social and economic power… become potentially world destroying

— Ray Peat

11.4% of U.S. adults have taken prescription medication for depression in the last 12 months.

More in Serotonin

Structure / Chemical properties

Unlike some other drug classes, SSRIs do not share a uniform chemical structure. They are primarily defined by their pharmacological activity: their ability to bind to the serotonin transporter (SERT) and inhibit its action.

However, it is notable that many of them contain halogen atoms (such as fluorine in fluoxetine or chlorine in sertraline).

From a bioenergetic standpoint, this can contribute to their toxicity and their interference with thyroid function, as halogens can compete with iodine and disrupt thyroid hormone synthesis.

Function / Mechanism of action

CUMS-depression rodent data suggest SSRI benefit may parallel progesterone through shared TNF-α suppression rather than sustained extracellular serotonin elevation. SSRIs block the serotonin transporter (SERT) at the presynaptic membrane. This prevents the reuptake of released serotonin, thereby increasing its concentration and the duration of its action in the synaptic cleft.

Medical uses / Effects

Treatment-resistant depression

A 48-week pramipexole augmentation trial in treatment-resistant depression found benefit when dopamine signaling was raised alongside continued SSRI therapy, contrasting with serotonin-only strategies.

"Because it hasn’t been possible to provide evidence to support the idea that serotonin is a mood elevator happy hormone, the industry has looked for some way to explain the therapeutic benefit that they claim. They have generally settled on the idea that the SSRIs, after several weeks of use, increase the synthesis of the progesterone metabolite allopregnanolone, in the brain. That does happen, but the synthesis of those defensive steroids is also increased by any injury to the brain" - Ray Peat

Since the serotonin hypotesis, chemical inbaalance and it's genetic basis is faulty, SSRIs don't really help, they numb, the only benefit is the increase in allopregnenalone as a defense mechanism of the brain. This treatment is ineffective as proven by the Meyer study found no relationship between how much the striatal occupancy and how much the patients actually felt better shown on the Hamilton scale.

Research shows there is no convincing evidence that depression is associated with, or caused by, lower serotonin concentrations or activity.

Autopsy of suicide victims show high serotonin levels.

Side / Adverse effects

Three months of antidepressant treatment (mainly escitalopram) reduced affective empathy and empathy-related brain activity in depressed patients, while baseline depression itself showed no empathy deficit, implicating the drugs, not the illness, in blunted empathic responding; the effect was not explained by general blunting of negative affect, since self-experienced pain ratings did not change.

Violent crime

In Tobin v. SmithKline Beecham (2001), a Wyoming jury found GlaxoSmithKline 80% responsible for the 1998 killing of Donald Schell's wife, daughter, and infant granddaughter, followed by his own suicide, hours after he started Paxil. The jury awarded $6.4 million in damages.

In a Swedish registry cohort of 785,337 SSRI-treated adults, antidepressant use associated with 26% higher odds of violent crime; elevated risk persisted up to 12 weeks after discontinuation and was strongest in patients with prior convictions. Ketamine's rapid antidepressant PET profile (more 5-HT1B receptors, less serotonin release, more dopamine) contrasts with chronic SSRI-driven synaptic serotonin elevation. Genetic loss of the serotonin transporter produced chronic anxiety and impaired fear extinction in mice, mirroring the elevated synaptic serotonin expected from SSRI therapy. Mild chronic serotonin syndrome from continued SSRI therapy presented with nonspecific symptoms and did not resolve until serotonergic drugs were stopped, with risk of acute escalation after dose changes. All six major SSRIs inhibited gonadal testosterone and DHT synthesis and lowered adrenal DHEA and progesterone in vitro, acting as endocrine disruptors beyond central serotonin reuptake blockade. Selective serotonin reuptake inhibitors were epidemiologically linked to microscopic colitis; experimental serotonin elevation impaired gut autophagy and worsened colitis severity. Eric Harris, one of the two Columbine High School shooters (1999), had therapeutic levels of fluvoxamine (Luvox), an SSRI he had been prescribed for about a year, in his system at autopsy; toxicology found no other substances. A single case doesn't establish causation, but it's the kind of individual data point the Swedish registry finding above would predict.

In 2010, an inquest into the death of 22-year-old Shane Clancy, who fatally stabbed 22-year-old Sebastian Creane before killing himself in Bray, Ireland, in August 2009, returned an open verdict. The pathologist found toxic levels of citalopram, an SSRI Clancy had been prescribed weeks earlier, in his system at autopsy.

Learning and behavioral control

Week-long citalopram shifted human reinforcement learning toward punishment and away from reward in computational models, without improving net decision quality.

Prenatal and neonatal neurodevelopment

Perinatal fluoxetine combined with maternal immune activation synergistically altered offspring neurobiology and behavior in a model relevant to autism risk.

Cardiac valve toxicity

Impaired serotonin-transporter activity in mitral-valve cells promoted myxomatous degeneration and regurgitation, directly linking reduced SERT function (the SSRI target) to structural heart-valve disease.

Neonatal behavioral toxicity

Neonatal fluoxetine exposure increased adult anxiety and forced-swim immobility in rats, whereas 5-HT7 antagonism blocked fluoxetine-induced behavioral changes without mimicking antidepressant benefit.

Prenatal and neonatal neurodevelopment

Perinatal fluoxetine impairs prefrontal excitatory synapse maturation via 5-HT2A and 5-HT7 receptor signaling, providing a direct serotonergic mechanism for SSRI-associated offspring brain hyperexcitability.

Chronic fatigue

Fluoxetine administration induced myalgic encephalomyelitis/chronic fatigue syndrome-like symptoms in mice through central serotonergic hyperactivity.

Cardiac toxicity

SSRI exposure suppresses mitochondrial respiration and ATP production in human stem-cell cardiomyocytes and cardiac organoids, disrupting sarcomere organization.

Hyponatremia

In 234,000 Swedish first-time SSRI/venlafaxine users, profound hyponatremia was most likely within three months of initiation (adjusted OR 4.3 vs. the prior year). https://x.com/pikeypilled/status/1884237602859147283

Luteal-phase dosing for PMDD

For premenstrual dysphoric disorder (PMDD) and severe PMS, expert guidelines endorse intermittent SSRI dosing restricted to the late luteal phase (from ovulation, or from about 14 days before menses, through menstruation onset) as an alternative to continuous daily dosing, alongside continuous and symptom-onset regimens. Critics note that repeatedly starting and stopping an SSRI each cycle, on top of the hormone swings luteal-phase dosing is meant to treat, has not been specifically followed up for suicidality risk; this concern is anecdotal/expressed on social media, not itself backed by a dedicated safety study.

Some are unknown to the public, because of deliberete withholding of information by the doctors, black-box warnings and hiding clinical data from the public

• Inability to feel love: Selective serotonin reuptake inhibitors were found to reduce the intensity and duration of feelings of love
• Loss of desire/libido:
  • In a Spanish study of 1022 patients
    • 57% experienced decreased libido
    • 57% experienced delayed orgasm or ejaculation
    • 46% experienced no orgasm or ejaculation
    • 31% experienced erectile dysfunction or decreased vaginal lubrication.
  • Post-SSRI Sexual Dysfunction (PSSD) can persist for years or become permanent; formally recognized by EMA in 2019
    • PSSD Network | Post-SSRI Sexual Dysfunction
• Learned helplessness: No drive to exit a toxic situation
• Emotional numbness: Anhedonia, decreased empathy
• Depersonalization
• Cognitive decline: Faster cognitive decline, 35% increased risk of severe dementia, earlier death for dementia patients
  • Symptoms also include: confusion, distorted thinking, convulsions, amnesia, brain-zaps
• Bone density loss: 25% increased fracture risk
• All-cause mortality. 18% increase
• Bipolar disorder: Significantly raises the risk
  • Studies:
    • SSRIs associated with a 7.7% annual rate of new bipolar diagnoses (tripling the baseline rate).
    • 60% had their first manic episode after starting antidepressants for depression.
    • 1 of 184 hospitalized patients on SSRIs developed mania and 8 became psychotic
      • 8% of 533 Yale admissions were for antidepressant-caused mania/psychosis.
• Violence:
  • A 2020 Swedish register-based study found that SSRI use is associated with an increased risk of violent crime convictions persisting during treatment and up to 12 weeks after discontinuation,
    • Raised serotonin itself even without supplementation is proven to increase violent tendencies
    • An earlier Swedish register cohort of 856,493 people prescribed SSRIs found the same age split: an overall 19% higher rate of violent crime conviction while on the drug versus off it in the same individuals, concentrated almost entirely in the 15-24 age group, where the rate was 43% higher. No significant association appeared in the 25-34, 35-44, or 45-and-older groups.
    • A meta-analysis of 70 double-blind placebo-controlled trials (18,526 patients, drawing on 64,381 pages of clinical study reports for duloxetine, fluoxetine, paroxetine, sertraline, and venlafaxine) found no significant increase in aggression or suicidality in adults, but in children and adolescents antidepressant use doubled the risk of suicidality (odds ratio 2.39) and nearly tripled the risk of aggressive behavior (odds ratio 2.79).
• Suicide:
  • In a trial, SSRIs doubled the risk of harms related to suicidality and violence in adult healthy volunteers with no mental disorder.
  • Study of 20 mentally healthy volunteers reported that Zoloft made 2 become suicidal, one close to actually comitting suicide, both of whom remained deeply disturbed for months.
• Antidepressant Withdrawal Syndrome

New Zealand survey on 1,829 patiensts: 62% reported sexual difficulties, 60% felt emotionally numb, 52% felt not like themselves, 39% cared less about others, 47% had experienced agitation and 39% had experienced suicidal ideation.

= Other adverse effects

Heart valve fibrosis

Long-term SSRI exposure correlates with earlier mitral-valve surgery; serotonin transporter genotype and pharmacologic SERT blockade promote mitral thickening in animal models. Raising synaptic serotonin with SSRIs can worsen tinnitus by hyperactivating cochlear-nucleus fusiform neurons; patients with hearing loss or tinnitus may need caution with serotonergic antidepressants.= Insomnia, nightmares, ‘Fuzzy’/‘zombie,’ jaw grinding, sweating, blurred vision, constipation, disturbed/restless sleep, anxiety, heart palpitations, difficulty thinking, fatigue/exhaustion, strange/vivid dreams, stiff muscles/joints,’ mania, excessive yawning, panic attacks, memory loss, decreased motivation, night sweats, decreased appetite, feeling agitated, shaky or anxious, indigestion, stomach aches and diarrhea.

Pregnancy adverse effects

shorter babies with smaller heads in mothers taking them during pregnancy

30% of babies will also experience “neonatal adaptation syndrome” (withdrawals) post birth.

• Impaired energy signaling in dorsal hippocampus causes depression/anxiety in stressed mice.
• Glucose hypometabolism in bilateral insula and cingulate gyrus in depressed individuals.
• No consistent association between low serotonin and depression.
• Declining basal metabolic rates and body temperatures not due to reduced activity.
• Doctors receiving payments prescribe tied drugs 58% more; pattern for 46/50 drugs.
• Positive association between payments and prescriptions in 30/36 studies.
• Reclassify 'suicide attempt' to 'overdose' and 'suicidal ideation' to 'depression'. Claude Bouchy memo, 1990 (Exhibits 117-118, Forsyth v. Eli Lilly)
• Evidence of being misled on fluoxetine safety.
• Large-scale underreporting of suicidality in fluoxetine data.
• 50,000 excess suicides attributable to Prozac since launch.
• Negative benefit-risk balance for Prozac in children under 18.

• Serotonergic antidepressants most implicated in violence reports.

Tapering off

"It takes time to adapt to decreasing those drugs, keeping sugar up and inflammation down, including bag breathing, should help. Starting with a little, a sixth or fourth of a tablet, of cynoplus in the evening would be the best way to try it." - Ray Peat

Getting the tapering off right is vital, having high metabolism and the right hormonal ballance lessens the "fall".

Keeping the metabolic rate and cholesterol up is important, so that repair and adaptation will be quick. Progesterone reduces pain and anxiety, and pregnenolone would be the most convenient supplement for men, but it's hard to find products without allergens. Combining progesterone and DHEA or testosterone can produce the stabilizing effect without suppressing the libido. Benadryl and cyproheptadine are probably both helpful. Withdrawal from morphine and SSRIs and migraine involve some similar processes.

It depends on how much pregnenolone you can assimilate. People would use progesterone in amounts needed to stop the withdrawal symptoms, but pregnenolone doesn't have the powerful effects of progesterone, even in multi-gram quantities, so it's just a matter of seeing what it can do. As I understand the mechanism (migraine, withdrawal, etc.), estrogen-histamine-serotonin rise on a background of hypothyroid liver malfunction, cytomel (and/or sugar, selenium, B vitamins) allows the liver and other detoxifying systems to lower them, and the lower they are, the less progesterone or pregnenolone it takes to block the symptoms.

Linear tapering

• Fixed dose reductions (e.g., 50% every 2-4 weeks) down to minimum therapeutic dose
• Simple, guideline-recommended, but can cause intense withdrawal symptoms (up to 78% in short tapers) due to abrupt SERT occupancy drops
  • Often leads to relapse misdiagnosis; success variable.

Discontinuation-induced relapse, misdiagnosed as relapse of illness

A meta-analysis of 27 placebo-controlled discontinuation studies (3,037 patients) found antidepressant discontinuation raised the monthly relapse rate more than threefold compared to continued treatment (6.24%/month vs. 1.85%/month), and roughly doubled the 12-month relapse risk (44.8% vs. 19.5%). The same pattern, a drug-withdrawal relapse mistaken for the return of the original condition rather than recognized as a withdrawal effect of the drug itself, recurs across antidepressants, antipsychotics, and mood stabilizers, and this risk is not typically included in the informed consent patients receive before starting or stopping these drugs.

Hyperbolic tapering

• Method for discontinuing SSRIs, proposed by Dr. Mark Horowitz in 2019.
• Larger initial dose reductions followed by progressively smaller reductions to minimize withdrawal symptoms, contrasting with traditional linear tapering.

Rationale

Based on the hyperbolic relationship between SSRI dosage and serotonin transporter (SERT) occupancy. Even small doses maintain significant SERT occupancy, necessitating gradual reductions at lower doses to avoid abrupt drops that trigger severe withdrawal effects.

Comparison with linear tapering

Linear tapering reduces doses by fixed amounts, which can lead to intense withdrawal symptoms at lower doses. Hyperbolic tapering mitigates this by aligning dose reductions with the drug's pharmacodynamic effects, resulting in milder and more manageable symptoms.

Implementation

The method recommends starting with larger reductions and slowing down as doses decrease, potentially extending over six to twelve months or longer. Options include using liquid formulations, compounding pharmacies, pill-cutting, or bead-counting for precise dosing. Specific schedules, such as reducing escitalopram from 10mg to 0mg in steps like 5mg, 3mg, 1.5mg, 1mg, 0.5mg, and 0.25mg, are highlighted as effective.

Managing withdrawal symptoms

Supportive measures are emphasized, including high-dose magnesium, thiamine (with caution on forms like TTFD initially), taurine, glycine, and L-theanine to balance GABA/glutamate and reduce excitotoxicity. Sodium supplementation is advised to counter hyponatremia, potentially using skimmed milk with salt. Avoiding additional serotonin-modulating agents during tapering is recommended to clearly identify withdrawal effects.

Potential challenges and considerations

Prolonged tapering might sometimes exacerbate symptoms in certain cases, leading to protracted withdrawal. A study advises monitoring for misinterpretation of withdrawal as relapse and suggests short term fluoxetine substitution for high-risk SSRIs, though fluoxetine is not self-tapering despite its long half-life.

Outcomes and evidence

Observational data indicates hyperbolic tapering is associated with limited, rate-dependent withdrawal symptoms, with success rates around 72% in case studies. It stresses the importance of personalized schedules and professional guidance to achieve antidepressant-free status without significant issues.

Brands and sources

Brands

• Zoloft (sertraline)
• Lexapro (escitalopram)
• Prozac (fluoxetine)
• Celexa (citalopram),
• Paxil (paroxetine),
• Luvox (fluvoxamine)